PHARMACOKINETICS OF SIMEPREVIR (TMC435) IN VOLUNTEERS WITH MODERATE OR SEVERE HEPATIC IMPAIRMENT

被引：13
|
作者：
Ouwerkerk-Mahadevan, S. [1 ]
Simion, A. [2 ]
Spittaels, K. [2 ]
Beumont-Mauviel, M. [2 ]
机构：
[1] Janssen Res & Dev, Beerse, Belgium
[2] Janssen Infect Dis BVBA, Beerse, Belgium
来源：
JOURNAL OF HEPATOLOGY | 2013年 / 58卷
关键词：
D O I：
10.1016/S0168-8278(13)60889-2
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
887
引用
下载
收藏
页码：S365 / S365
页数：1
相关论文
共 50 条
  • [31] Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Ozanimod
    Zhang, Peijin
    Hosein, Fareeda
    Yu, Kyungha
    Walker, Susan
    Syto, Mary
    Tirucherai, Giridhar
    Murthy, Bindu
    Tatosian, Daniel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S843 - S843
  • [32] An effect of moderate hepatic impairment on the pharmacokinetics and safety of darapladib
    Magee, Mindy He
    Shearn, Shawn
    Shaddinger, Bonnie
    Fang, Zixing
    Glaser, Ruchira
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (05) : 1014 - 1021
  • [33] Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
    Tortorici, Michael A.
    Toh, Melvin
    Rahavendran, S. V.
    LaBadie, Robert R.
    Alvey, Christine W.
    Marbury, Thomas
    Fuentes, Ernesto
    Green, Matthew
    Ni, Grace
    Hee, Brian
    Pithavala, Yazdi K.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (06) : 1370 - 1380
  • [34] Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment
    Almeida, Luis
    Potgieter, J. Hendrick
    Maia, Joana
    Potgieter, M. Alida
    Mota, Fernando
    Soares-da-Silva, P.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (03) : 267 - 273
  • [35] Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
    Akce, Mehmet
    El-Khoueiry, Anthony
    Piha-Paul, Sarina A.
    Bacque, Emeline
    Pan, Peng
    Zhang, Zhi-Yi
    Ewesuedo, Reginald
    Gupta, Divya
    Tang, Yongqiang
    Milton, Ashley
    Zajic, Stefan
    Judson, Patricia L.
    O'Bryant, Cindy L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 88 (05) : 825 - 836
  • [36] Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
    Schnell, David
    Buschke, Susanne
    Fuchs, Holger
    Gansser, Dietmar
    Goeldner, Rainer-Georg
    Uttenreuther-Fischer, Martina
    Stopfer, Peter
    Wind, Sven
    Petersen-Sylla, Marc
    Halabi, Atef
    Koenen, Ruediger
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (02) : 267 - 275
  • [37] Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment
    Wang, Jing
    Wang, Xiaodong
    Zhang, Zhi-Yi
    Arora, Sujata
    Lu, Sharon
    Kansra, Vikram
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (05): : 686 - 693
  • [38] Lack of Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Telavancin
    Goldberg, Michael R.
    Wong, Shekman L.
    Shaw, Jeng-Pyng
    Kitt, Michael M.
    Barriere, Steven L.
    PHARMACOTHERAPY, 2010, 30 (01): : 35 - 42
  • [39] Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
    Michael A. Tortorici
    Melvin Toh
    S. V. Rahavendran
    Robert R. LaBadie
    Christine W. Alvey
    Thomas Marbury
    Ernesto Fuentes
    Matthew Green
    Grace Ni
    Brian Hee
    Yazdi K. Pithavala
    Investigational New Drugs, 2011, 29 : 1370 - 1380
  • [40] Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam
    Kletzl, Heidemarie
    Ajmi, Hassan
    Antys, Izabela
    Heinig, Katja
    Jaber, Birgit
    Marbury, Thomas C.
    Young, Annie
    Gunther, Andreas
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (08) : 3749 - 3759
12345